MENU
Showcases Stock ranks Forex

Chembio Diagnostics (CEMI)
0.455  0.001 (0.22%) 04-27 16:00
Open: 0.45 Pre. Close: 0.454
High: 0.455 Low: 0.455
Volume: 351,642 Market Cap: 17(M)
Stock Technical Analysis
Overall:     
Target: Six months: 0.55
One year: 0.64
Support: Support1: 0.38
Support2: 0.33
Resistance: Resistance1: 0.47
Resistance2: 0.55
Pivot: 0.45
Moving Averages: MA(5): 0.45
MA(20): 0.45
MA(100): 0.38
MA(250):
MACD: MACD(12,26): 0.01
Signal(12,26,9): 0.01
%K %D: %K(14,3): 71.79
%D(3): 67.81
RSI: RSI(14): 58.08
52-Week: High: 1.24
Low: 0.19
Change(%): -20.5
Average Vol(K): 3-Month: 674
10-Days: 227
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.46 - 0.463 0.463 - 0.465
Low: 0.454 - 0.457 0.457 - 0.459
Close: 0.456 - 0.46 0.46 - 0.464
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ CEMI ] has closed below upper band by 31.7%. Bollinger Bands are 74.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Stock chart
Stock News
Mon, 10 Apr 2023
Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023 - Yahoo Finance

Thu, 06 Apr 2023
CHEMBIO DIAGNOSTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer ... - Marketscreener.com

Wed, 01 Feb 2023
Chembio Diagnostics Agrees to $17.2 Million Takeover by Biosynex; Shares Rise Pre-Bell - Marketscreener.com

Wed, 01 Feb 2023
French Rapid Testing Company Scoops Up Chembio Diagnostics For $17M - Yahoo Finance

Wed, 01 Feb 2023
White & Case Advises Biosynex on Merger Agreement With Chembio Diagnostics, Inc. - White & Case LLP

Tue, 31 Jan 2023
Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement - GlobeNewswire

Financial Analysis
Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. (M) 36.73
Shares Float (M) 30.93
% Held by Insiders 2.39
% Held by Institutions 21.67
Shares Short (K) 292
Shares Short Prior Month (K) 327
Stock Financials
EPS -0.720
Book Value (p.s.) 0.490
Profit Margin -47.03
Operating Margin -41.20
Return on Assets (ttm) -18.8
Return on Equity (ttm) -89.5
Qtrly Rev. Growth -49.7
Gross Profit (p.s.) 0.106
Sales Per Share 1.348
EBITDA (p.s.) -0.486
Qtrly Earnings Growth
Operating Cash Flow (M) -12.69
Levered Free Cash Flow (M) -8.71
Stock Valuation
PE Ratio -0.63
PEG Ratio
Price to Book value 0.93
Price to Sales 0.34
Price to Cash Flow -1.32
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android